Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

European journal of clinical pharmacology - 1 Jan 1991

Veronese M E, McLean S

Abstract excerpt

The metabolism of paracetamol and phenacetin has been studied in subjects previously phenotyped as either extensive or poor metabolisers of debrisoquine (EM and PM, respectively), in order to examine the relationship between phenacetin and paracetamol activation and debrisoquine oxidation status. In separate experiments, paracetamol and phenacetin were administered orally to groups of 5 EM and 5 PM subjects, and...

Topics

Acetaminophen
Adult
Biotransformation
Debrisoquin
Female
Humans
Male
Oxidation-Reduction
Phenacetin
Phenotype

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 1884734
DOI: 10.1007/BF00279967

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-1884734-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.PMID 1884734Read ↗

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.Semantic proximity Read ↗

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.Semantic proximity Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.Semantic proximity Read ↗

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.Semantic proximity Read ↗

Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.Semantic proximity Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.